Juan Sanchez
Director · Nuvectis Pharma, Inc.
- 2025
- Jun 12, 2026
- 3
Summary
Latest filing:
Juan Sanchez is Director of Nuvectis Pharma, Inc. (NVCT). 3 SEC Form 4 filings on record going back to 2025, most recently on 12 June 2026. Most recent open-market trade: bought $75K of NVCT on 6 November 2025. Lifetime open-market purchases: $75K.
Recent transactions
3The latest 3 SEC Form 4 transactions reported by Juan Sanchez.
Trading pattern
InsiderAlpha's records for Juan Sanchez go back to 2025: 3 primary Form 4 filings, an average of 1.5 per year. The typical open-market purchase is $75K (1 buy totaling $75K). The largest single buy on record is $75K of NVCT in 2025. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Juan Sanchez files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Marlio Charles Mosseri - $916K in NVCT purchases and sales in the last 12 months
- Ron Bentsur - $279K in NVCT purchases and sales in the last 12 months
- Matthew L. Kaplan - $64K in NVCT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Juan Sanchez?
Juan Sanchez is a corporate insider, tracked as Director of Nuvectis Pharma, Inc. (NVCT). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Juan Sanchez last file a Form 4?
The most recent primary Form 4 on record is dated 12 June 2026, one of 3 filings going back to 2025.
Has Juan Sanchez been buying or selling stock?
Recorded transactions: 1 open-market purchase ($75K) and 0 open-market sales across all tracked filings.